$ABBV

24 stories mentioning ABBV

Every FINWIRES story that references ABBV, newest first.

Research Alert: CFRA Keeps Buy Rating On Shares Of Abbvie Inc.

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:We lower our target price to $255 from $275, 15.8x our 2026 EPS view. This is above ABBV's 10-year historical forward P/E average of 12.0x, justified by the company's improving long-term growth prospects. We lower our 2026 EPS forecast to $14.02 from $14.29 as we adjust our Q1 EPS estimate to $2.63 from $3.05. The company disclosed a new IPR&D and milestone expense of $744M last week related to collaborations, licensing agreements, and asset acquisitions, which will dilute Q1 EPS. We keep our 2026 EPS estimate at $16.13. The company is expected to report Q1 results before market open on April 29, when we expect to get more color on Q1 performance and expectations for the remainder of 2026.

$ABBV

Sectors66d ago

Sector Update: Health Care Stocks Fall Late Afternoon

Health care stocks declined late Friday afternoon, with the NYSE Health Care Index falling 1.1% and the State Street Health Care Select Sector SPDR ETF (XLV) dropping 1.4%.The iShares Biotechnology ETF (IBB) shed 1.7%.In corporate news, AbbVie (ABBV) is expected to report Q1 earnings within its guidance range, but that may not be enough to improve sentiment toward the drugmaker, RBC Capital Markets said in a client note. The brokerage expects AbbVie to report per-share earnings of $2.59 for the first quarter, while the current consensus on FactSet is for non-GAAP EPS of $2.83. AbbVie shares were down 2.1%.Replimune (REPL) shares tumbled 19%. The company's biologics license application for vusolimogene oderparepvec to treat unresectable advanced cutaneous melanoma was rejected by the US Food and Drug Administration, the regulator said in a complete response letter.Abbott Laboratories (ABT) has been ordered by a jury in Chicago to pay $53 million in compensatory damages to a group of families related to four cases over its infant formula, the Chicago Tribune reported. The families accused the company of allegedly failing to inform them that its infant formula could develop a dangerous intestinal disease in premature infants, the report said. Abbott shares fell 2.7%.Organon (OGN) is closing in on a deal to be acquired by Sun Pharmaceutical Industries for $12 billion, The Economic Times reported. Organon shares surged 27%.

$ABBV$ABT$OGN$REPL

Sectors66d ago

Sector Update: Health Care

$ABBV

US Markets66d ago

AbbVie First-Quarter Earnings Unlikely to Lift Sentiment, RBC Says

AbbVie (ABBV) is expected to report first-quarter earnings within its guidance range, but that may not be enough to improve sentiment toward the drugmaker, RBC Capital Markets said in a Friday client note.The brokerage expects AbbVie to report per-share earnings of $2.59 for the first quarter, while the current consensus on FactSet is for non-GAAP EPS of $2.83.Earlier in April, AbbVie revised its first-quarter adjusted EPS outlook to a range of $2.56 to $2.60. The company said it expected a pre-tax charge of $744 million related to acquired in-process research and development and other expenses to negatively impact its bottom line by $0.41 a share."We think the bar is high for (AbbVie), and 'in-line' results may not be enough to turn the tide on the negative sentiment," RBC analyst Trung Huynh wrote in the note. "Unless the company delivers a clear beat, we see the current malaise persisting into (the second quarter of 2026)."AbbVie is scheduled to release its latest quarterly results on April 29.Sales of the company's immunology drugs, Skyrizi and Rinvoq, in the first quarter are tracking with consensus and guidance, according to RBC. The brokerage anticipates a "small" year-over-year decline in AbbVie's oncology segment, impacted by Inflation Reduction Act pricing erosion and decreasing volume for cancer drug Imbruvica.RBC forecasts the company to report revenue of $14.82 billion, while the Street is looking for $14.73 billion.The brokerage has an outperform rating on AbbVie's stock with a price target of $260.

$ABBV

Showing 21-24 of 24